The Role of IL-22/IL-22BP Axis in Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Registration Number
- NCT04310189
- Lead Sponsor
- Nantes University Hospital
- Brief Summary
Interleukin 22 (IL-22) is known to be regulated by IL-22 binding protein (IL-22BP), a soluble, inhibitory receptor. The potential role of IL-22BP in atopic dermatitis (AD) is mostly unknown and deserves further investigation. The main objective of this study is to better understand the potential protective role of IL-22BP through the assessment of its expression at the Messenger Ribonucleic Acid (mRNA) and protein levels in skin and serum which will be correlated to the severity of the diseases and through the identification of its cellular sources in lesions. The results of this study will help to correctly interpret the levels of IL-22 in AD and will potentially allow identifying biomarkers for patient stratification and predicting clinical outcomes to targeted therapeutic agents.
- Detailed Description
This is a single-visit study. All patients will have a blood sample and 2 skin biopsies (2 mm diameter) in lesional and non lesional area
. It is planned to include 45 patients (15 patients per severity group: SCORAD \]25-50\] , \]50-65\]; 50-65; \>65).The first 20 patients included will be group 2 and 3 patients (SCORAD \> 50).
The patients will be adults with AD recruited from the cohort of patients followed up in the Dermatology department of Nantes University Hospital. A refusal rate of 4/5 is expected. Recruitment can therefore be envisaged in 18 months (2.5 patients/month). Patients will be recruited during follow-up consultations or at the first consultation in the department. Recruitment will be coordinated by the clinical research team (CRT). Blood samples will be taken by the CRT Nurse. The skin and blood samples will be sent to the CIMNA/ Immunology Laboratory Nantes University hospital
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 45
- Patients with AD according to UK Working Party criteria
- Patients affiliated to French social security system
- Patients who gave written consent after reading the protocol
- Moderate to severe AD (SCORAD score>25)
- Presence of at least one lesional and one non-lesional skin area in the area covered by the clothing
- No immunosuppressive systemic treatment in progress for at least 3 months or biologics for at least 4 months
- Minor patients
- Pregnant and/or breastfeeding women
- Patients under guardianship or tutorship
- Inability to understand information and instructions
- Patients undergoing systemic immunosuppressive treatment for at least 3 months or biologics for at least 4 months
- Patient included in a clinical trial
- Documented allergy to the anesthetic (xylocain)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Expression levels of IL-22 at the transcriptomic level 1 day To compare the expression levels of IL-22 at the transcriptomic level in non lesional and lesional skin between the different groups of AD patients included in the study.
Three groups of patients will be defined based on the SCORAD score . The score is out of 103 and is higher the greater the severity of the disease:
* Group 1: SCORAD score between \]25-50\]
* Group 2: SCORAD between \]50; 65\]
* Group 3: SCORAD greater than 65.
- Secondary Outcome Measures
Name Time Method IL-22 expression levels in lesional skin at the protein level 1 day To compare IL-22 expression levels in lesional skin at the protein level between the different AD patient groups included in the study.
level of IL22BP gene expression in in lesional and non lesional 1 day To compare the level of IL22BP gene expression in in lesional and non lesional in each patient group.
The level of IL-22-induced gene expression in lesional and non-lesional skin 1 day To compare the level of IL-22-induced gene expression in lesional and non-lesional skin in each patient group: S100A8, involucrin, loricrin...
Locating IL-22 Binding protein (BP) 1 day Locating IL-22 Binding protein (BP) producing cells in the lesional skin of patients with a SCORAD\>50 (n = 10) (qualitative)
Characterizing IL-22 Binding protein (BP) 1 day Characterizing (phenotype) IL-22 Binding protein (BP) producing cells in the lesional skin of patients with a SCORAD\>50 (n = 10) (qualitative)
expression levels of IL-22BP at the transcriptome level in in lesional skin 1 day To compare the expression levels of IL-22BP at the transcriptome level in in lesional skin between the different groups of AD patients included in the study.
expression levels of IL-22BP at the protein level in lesional 1 day To compare the expression levels of IL-22BP at the protein level in lesional skin between the different groups of AD patients included in the study.
level of IL22R gene expression in lesional skin 1 day To compare the level of IL22R gene expression in lesional skin between different groups of patients.
Level of IL-22BP and IL-22 proteins in serum 1 day Measuring the level of IL-22BP and IL-22 proteins in serum
level of IL22 gene expression in lesional and non lesional skin 1 day To compare the level of IL22 gene expression in lesional and non lesional skin within each patient group
the level of IL22 receptor (IL22R ) gene expression in in lesional and non lesional skin 1 day Compare the level of IL22 receptor (IL22R ) gene expression in in lesional and non lesional skin within each patient group
The level of expression of the following IL-22-induced genes 1 day To compare the level of expression of the following IL-22-induced genes in injured skin between different groups of AD patients: S100A8, involucrin, loricrin
Trial Locations
- Locations (1)
Nantes University Hospital
🇫🇷Nantes, France